Avid Bioservices Inc (CDMO)

[biopharm]

Oct 2013 When will BXQ-350 nanovesicles be available for treating cancer patients?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92701446

Oct 2013
Former fda commissioner joinened Bexion in 2011.Smells fishy.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=92701660

MARCH 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112021208

May 2016
Competing interests
Xiaoyang Qi, Ph.D. is listed as an inventor on the patent for the technology (SapC-DOPS) that is the subject of this research. Consistent with current Cincinnati Children’s Hospital Medical Center policies, the development and commercialization of this technology has been licensed to Bexion Pharmaceuticals, LLC, in which Dr. Qi holds a minor (<5 %) equity interest. This work was supported in part by R01CA158372-01A0 (to X. Qi), R21NS095047-01A0 (to X. Qi), Brain Tumor Center Research Funds and Hematology-Oncology Programmatic Support from University of Cincinnati College of Medicine (to X. Qi), and New Drug State Key Project Grant Number 009ZX09102-205 (to X. Qi).
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-016-0519-1


Feb 2017
SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128826979